The specific physiological background induced by pregnancy leads to significant changes in maternal pharmacokinetics, suggesting potential variability in plasma concentrations of antiretrovirals. Therefore, pregnant women may be exposed to subtherapeutic doses, particularly in the later stages of pregnancy, which may increase the risk of HIV transmission from mother to child.